Fulgent Genetics (FLGT) EBT (2015 - 2026)

Fulgent Genetics has reported EBT for 12 years, with the latest figure at -$29.7 million in Q2 2026.

• Quarterly EBT fell 37.97% year-over-year to -$29.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$92.5 million (down 54.55% YoY) and the FY2025 annual result came in at -$70.0 million, down 34.78% from the prior year.
• EBT retreated to -$29.7 million in Q2 2026 per FLGT's latest filing, from -$26.0 million in the prior quarter.
• Over five years, EBT peaked at $202.0 million in Q1 2022 and troughed at -$145.2 million in Q4 2023.
• A 5-year average of -$9.3 million and a median of -$14.4 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2024: EBT surged 290.44% in 2023, then tumbled 370.15% in 2024.
• Over 5 years, EBT stood at -$33.5 million in 2022, then slumped by 333.91% to -$145.2 million in 2023, then jumped by 94.46% to -$8.0 million in 2024, then plunged by 263.88% to -$29.3 million in 2025, then fell by 1.42% to -$29.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$29.7 million, -$26.0 million, and -$29.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.